Physician profile
Boris Kaim
NPI 1326054164
$5,793.99
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $1,449 · 2021: $1,285 · 2022: $1,129 · 2023: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $438.87 | 2019-2023 | Mavenclad |
| Ucb, INC. | $352.40 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $343.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $325.61 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $318.70 | 2019-2023 | Rytary |
| Abbvie INC. | $312.81 | 2019-2023 | |
| Lilly USA, LLC | $306.84 | 2019-2023 | Reyvow, Emgality |
| Genzyme Corporation | $276.81 | 2019-2021 | |
| Genentech USA, INC. | $268.02 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $208.12 | 2019-2023 | Ultomiris |
| Amgen INC. | $203.68 | 2020-2022 | |
| Biogen, INC. | $199.69 | 2019-2022 | |
| Neurelis, INC. | $190.98 | 2021-2023 | Valtoco |
| Sk Life Science, INC. | $187.21 | 2020-2022 | |
| Medtronic USA, INC. | $177.09 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $157.31 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $144.50 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $134.71 | 2019-2021 | |
| Lundbeck LLC | $129.22 | 2020-2023 | Vyepti |
| Medtronic, INC. | $118.91 | 2022 | |
| Neuronetics, INC. | $100.00 | 2020 | |
| Arbor Pharmaceuticals, INC. | $96.80 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $91.04 | 2019-2022 | |
| Celgene Corporation | $83.99 | 2020-2022 | |
| Allergan, INC. | $79.82 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $75.50 | 2019-2021 | |
| Csl Behring | $73.95 | 2020-2021 | |
| Harmony Biosciences LLC | $70.16 | 2020-2021 | |
| Eisai INC. | $60.29 | 2019-2021 | |
| Acorda Therapeutics, INC | $58.37 | 2019-2020 | |
| Horizon Therapeutics Plc | $51.83 | 2021-2022 | |
| Argenx US, INC. | $43.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.14 | 2020-2022 | |
| Tanabe Pharma America, INC. | $23.20 | 2022 | |
| Ge Healthcare | $16.45 | 2019 | |
| Kyowa Kirin, INC. | $16.42 | 2020 | |
| Mdd US Operations, LLC | $15.24 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Kaim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.